{"filing":{"accession_number":"0001493152-26-032085","cik":"0001113423","ticker":"CSCIF","company_name":"COSCIENS Biopharma Inc.","form":"6-K","filing_date":"2026-07-06","report_date":null,"primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1113423/000149315226032085/form6-k.htm"},"events":[{"id":16138,"run_id":14401,"accession_number":"0001493152-26-032085","anchor_item_number":"EX-99.1","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The exhibit announces completion of a previously announced share consolidation (1:150 ratio) followed by an immediate split (50:1 ratio), resulting in a net 3:1 reduction in shareholder interests. This is a material capital structure modification affecting all shareholders' ownership percentages. The disclosure also notes the Company's intent to file Form 15 to suspend U.S. reporting obligations, signaling a shift in listing status. While not a traditional governance event like an election or bylaw amendment, this share capital amendment is a material governance/corporate action that affects shareholder rights and the Company's regulatory posture.","company_name":"COSCIENS Biopharma Inc.","ticker":"CSCIF","filing_date":"2026-07-06","form":"6-K","submitted_at":null,"items":[{"id":14141,"accession_number":"0001493152-26-032085","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The exhibit announces completion of a previously announced share consolidation (1:150 ratio) followed by an immediate split (50:1 ratio), resulting in a net 3:1 reduction in shareholder interests. This is a material capital structure modification affecting all shareholders' ownership percentages. The disclosure also notes the Company's intent to file Form 15 to suspend U.S. reporting obligations, signaling a shift in listing status. While not a traditional governance event like an election or bylaw amendment, this share capital amendment is a material governance/corporate action that affects shareholder rights and the Company's regulatory posture.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-06T12:32:04.953664+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14141,"accession_number":"0001493152-26-032085","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The exhibit announces completion of a previously announced share consolidation (1:150 ratio) followed by an immediate split (50:1 ratio), resulting in a net 3:1 reduction in shareholder interests. This is a material capital structure modification affecting all shareholders' ownership percentages. The disclosure also notes the Company's intent to file Form 15 to suspend U.S. reporting obligations, signaling a shift in listing status. While not a traditional governance event like an election or bylaw amendment, this share capital amendment is a material governance/corporate action that affects shareholder rights and the Company's regulatory posture.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-06T12:32:04.953664+00:00","company_name":"COSCIENS Biopharma Inc.","ticker":"CSCIF","filing_date":"2026-07-06"}]}